Search | Clinical Trials Finder

Conditions: Surgery
Interventions: LapBox Manual Containment System, Standard of Care Specimen Bag; Device
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years to 65 Years · Female only
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma
Interventions: Panitumumab-IRDye800, Indium In 111 Panitumumab, Single Photon Emission Computed Tomography, Computed Tomography, Resection, Fluorescence Imaging; Drug · Other · Procedure
Lead sponsor: Vanderbilt-Ingram Cancer Center; Other
Eligibility: 19 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Retinal Disease
Interventions: IRX-101, Providone-Iodine; Drug
Lead sponsor: iRenix Medical, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 155 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2026
U.S. locations: 7
States / cities: Greenwich, Connecticut • Madison, Mississippi • Erie, Pennsylvania + 4 more

Conditions: Acute Myeloid Leukemia
Interventions: Bleximenib, Cytarabine, Daunorubicin or Idarubicin, Placebo; Drug
Lead sponsor: Stichting Hemato-Oncologie voor Volwassenen Nederland; Other
Eligibility: 18 Years and older
Enrollment: 875 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2033
U.S. locations: 11
States / cities: Los Angeles, California • San Francisco, California • Orlando, Florida + 8 more

Conditions: Lung Non-Squamous Non-Small Cell Carcinoma, Radiation-Induced Pneumonitis, Stage II Lung Non-Small Cell Cancer AJCC v7, Stage IIA Lung Non-Small Cell Carcinoma AJCC v7, Stage IIB Lung Non-Small Cell Carcinoma AJCC v7, Stage III Lung Non-Small Cell Cancer AJCC v7, Stage IIIA Lung Non-Small Cell Cancer AJCC v7, Stage IIIB Lung Non-Small Cell Cancer AJCC v7, Stage IV Lung Non-Small Cell Cancer AJCC v7
Interventions: Durvalumab, Nintedanib, Placebo, Quality-of-Life Assessment; Biological · Drug · Other + 1 more
Lead sponsor: Roswell Park Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Infection Prophylaxis
Interventions: SAR279356, placebo; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 6
States / cities: Los Angeles, California • Stanford, California • Jacksonville, Florida + 3 more

Conditions: Spasticity
Interventions: Phase 2; Low Dose MYOBLOC (15,000 Units), Phase 2; High Dose MYOBLOC (20,000 Units), Phase 2; Placebo, Phase 3; MYOBLOC, Phase 3; Placebo; Drug
Lead sponsor: Solstice Neurosciences, LLC, a subsidiary of MDD US Operations, LLC; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 4
States / cities: Downey, California • Boise, Idaho • Port Royal, South Carolina + 1 more

Conditions: Schizophrenia
Interventions: SEP-363856, Prior antipsychotic (risperidone, olanzapine, quetiapine or aripiprazole); Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 4
States / cities: Little Rock, Arkansas • Rogers, Arkansas • Dayton, Ohio + 1 more

Conditions: Sinusitis
Interventions: Restora™ Steroid eluting spacer, Silastic Silicone Spacer; Device
Lead sponsor: Cedars-Sinai Medical Center; Other
Eligibility: 18 Years to 75 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: COVID-19
Interventions: Remdesivir, RDV Placebo, Standard of Care; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 12 Years and older
Enrollment: 249 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 41
States / cities: Birmingham, Alabama • Mobile, Alabama • Eureka, California + 33 more

Conditions: Infections, Gram-positive Bacterial
Interventions: Telavancin, vancomycin or antistaphylococcal penicillin; Drug
Lead sponsor: Cumberland Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 201 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004
U.S. locations: 1
States / cities: National City, California

Conditions: Post-operative Pain
Interventions: Bupivacaine, Botulinum Toxins, Analgesics; Drug
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Systemic Lupus Erythematosus
Interventions: Enpatoran low dose, Enpatoran medium dose, Enpatoran high dose, Placebo; Drug
Lead sponsor: EMD Serono Research & Development Institute, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 456 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 14
States / cities: Torrance, California • Brandon, Florida • Miami, Florida + 10 more

Conditions: Diffuse Large B-Cell Lymphoma
Interventions: Bridging Radiation Therapy; Other
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Multiple Myeloma
Interventions: Uproleselan, Placebo, Melphalan; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years to 75 Years
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Alzheimers Disease
Interventions: Semaglutide, Placebo; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 55 Years to 75 Years
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 2
States / cities: Sun City, Arizona • Delray Beach, Florida

Conditions: Charcot-Marie-Tooth Disease
Interventions: Home Ankle Strengthing Program, Standard of Care; Other
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: COVID-19
Interventions: SOC + Intravenous Famotidine, SOC + Placebo; Drug
Lead sponsor: Northwell Health; Other
Eligibility: 18 Years and older
Enrollment: 233 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 5
States / cities: Bay Shore, New York • Manhasset, New York • Mount Kisco, New York + 2 more

Conditions: Critical Illness, Pneumonia
Interventions: High dose inhaled nitric oxide, Sham treatment, standard therapy; Drug · Other
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Hepatitis C
Interventions: Sofosbuvir, Placebo, PEG, RBV; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 6
States / cities: San Francisco, California • Gainesville, Florida • Orlando, Florida + 3 more

Conditions: Systemic Lupus Erythematosus
Interventions: Anifrolumab, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 6
States / cities: Thousand Oaks, California • Orlando, Florida • New York, New York + 3 more

Conditions: Frail Older Adults
Interventions: CogXergaming, Matter of Balance Training; Behavioral
Lead sponsor: University of Illinois at Chicago; Other
Eligibility: 60 Years and older
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Coronary Artery Disease
Interventions: Clopidogrel, Prasugrel, ticagrelor, aspirin, rivaroxaban; Drug
Lead sponsor: University of Florida; Other
Eligibility: 18 Years and older
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Arthritis, Rheumatoid
Interventions: CP-690,550, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 800 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 37
States / cities: Huntsville, Alabama • Tucson, Arizona • San Diego, California + 32 more

Search by objective public record fields.

LapBox® Manual Containment System

Evaluating the Use of Dual Imaging Techniques for Detection of Disease in Patients With Head and Neck Cancer

SteRilizing Eye SoLution to ImprovE Patient ComFort (RELIEF)

Bleximenib in Combination With Standard Induction and Consolidation Therapy Followed by Maintenance for Treatment of Patients With Acute Myeloid Leukemia (AML)

Nintedanib Compared With Placebo in Treating Against Radiation-Induced Pneumonitis in Patients With Non-small Cell Lung Cancer That Cannot Be Removed by Surgery and Are Undergoing Chemoradiation Therapy

Pharmacokinetics, Pharmacodynamics and Safety Evaluation of SAR279356 in Intensive Care Unit Mechanically Ventilated Patients

Efficacy and Safety Study of MYOBLOC® in the Treatment of Adult Lower Limb Spasticity

A Clinical Study That Will Assess the Effect of SEP-363856 or Prior Antipsychotic (PA) Standard of Care on Body-weight Associated Parameters in Subjects With Schizophrenia

Rates of Middle Meatus Synechiae Formation Post Endoscopic Sinus Surgery

Study to Evaluate the Efficacy and Safety of Remdesivir in Participants With Severely Reduced Kidney Function Who Are Hospitalized for Coronavirus Disease 2019 (COVID-19)

Phase 2 Trial of TD-6424 (Telavancin) Versus Standard Therapy for Complicated Gram Positive Skin and Skin Structure Infections (Gram Positive cSSSI)

A Prospective Trial to Reduce Post-Operative Pain in Implant Based Breast Reconstruction

The WILLOW Study With M5049 in SLE and CLE (SCLE and/or DLE) (WILLOW)

Hyperfractionated Dual Equivalent Fractionated Radiation Therapy

Uproleselan (GMI-1271) for GI Toxicity Prophylaxis During Melphalan-Conditioned Autologous Hematopoietic Cell Transplantation (Auto-HCT) for Multiple Myeloma (MM)

A Research Study Looking at the Effect of Semaglutide on the Immune System and Other Biological Processes in People With Alzheimer's Disease

Change in MUNIX in Patients With CMT1A Undergoing a Home Ankle Strengthening Program Versus Standard of Care

Multi-site Adaptive Trials for COVID-19

iNO300 Therapy in Critically Ill Patients With Pneumonia

Dose-Ranging Study of Sofosbuvir in Combination With Pegylated Interferon and Ribavirin in Treatment Naïve GT 1 HCV Patients

A Study to Characterize the Pharmacokinetics, Pharmacodynamics, and Safety of Anifrolumab in Adult Type I Interferon Test High Systemic Lupus Erythematosus Subject With Active Skin Manifestations

CogXergaming to Promote Physical Activity and Cognitive Function in Frail Older Adults

Switching From DAPT to Dual Pathway Inhibition With Low-dose Rivaroxaban in Adjunct to Aspirin in Patients With Coronary Artery Disease

A 2-Year Phase 3 Study Of CP-690,550 In Patients With Active Rheumatoid Arthritis On Background Methotrexate